Psoriasis Archives - Medical Conferences

Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

Presented By

Prof. Adam Reich, Medical College of Rzeszow, Poland

Trial

Phase 3, GEMINI-1; GEMINI-2

Conference

EADV 2024

Type

News article

1 October 2024 11:55

PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, Univeristy of Hamburg, Germany

Conference

EADV 2024

Type

News article

1 October 2024 11:50

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

Genetic and immunological advances in risk assessment and treatment of psoriatic diseases

Presented By

Prof. Wilson Liao, University of California San Francisco, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:32

Depression complicates the management of psoriatic disease

Presented By

Dr Wiebke Sondermann, University Hospital Essen, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:20

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Managing obesity and fibromyalgia in psoriatic disease

Presented By

Prof. Philip Mease, University of Washington, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:08

Multiple novel oral agents show promise in psoriasis

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

FRONTIER; STRIDE

Conference

IFPA 2024

17 July 2024 14:04

Biologics for psoriasis: towards oral therapies and less frequent dosing

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Trial

LIMMItless; GUIDE; FRONTIER

Conference

IFPA 2023

Type

News article

17 July 2024 14:00

Advances in psoriasis treatment: topical therapies show promising results

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

PSOARING; DERMIS

Conference

IFPA 2024

Type

News article

17 July 2024 13:49

Diagnosing generalised pustular psoriasis

Presented By

Dr Siew Eng Choon, Monash University Malaysia

Conference

IFPA 2024

Type

News article

17 July 2024 13:37

Itch and pain are major components of psoriatic disease and require management

Presented By

Prof. Adam Reich; Dr Anushka Irani

Conference

IFPA 2024

Type

News article

17 July 2024 12:07

Can diet help with the management of psoriasis?

Presented By

Prof. Wendy Hall, King's College London, UK

Trial

APPLE; METRED-P

Conference

IFPA 2024

Type

News article

17 July 2024 12:00

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

Robust long-term efficacy of bimekizumab in psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

BE BRIGHT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:09

Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 2, STRIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial

Expert

Dr Andrew Blauvelt

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April 2024 12:12

Interview: Medicare’s first drug price negotiations: concerning?

Expert

Prof. Marc Bonaca, University of Colorado, USA

4 January 2024 15:06

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:50

Analysing the Link Between Psoriasis and Chronic Kidney Disease

20 October 2023 12:20

Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings

Trial

Review study, GRAPPA

20 October 2023 12:15

Botulinum toxin A might provide efficacious treatment option for nail psoriasis

Presented By

Dr Premjit Juntongjin, Thammasat University, Thailand

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:53

POETYK PSO-1 and 2: Long-term efficacy results of deucravacitinib in plaque psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

POETYK PSO-LTE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:52

Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:35

Subcutaneous spesolimab for GPP flare prevention

Presented By

Prof. Bruce Strober, Yale University School of Medicine, CT, USA

Trial

Effisayil 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:32

Knocking out psoriasis with high-dose risankizumab?

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 2, KNOCKOUT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:30

Deucravacitinib versus other systemic therapies in Asian patients with psoriasis

Presented By

Prof. Tsen-Fang Tsai, (National Taiwan University Hospital, Taiwan

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:26

Vascular inflammation may be characteristic of PsA

Presented By

Dr Nienke Kleinrensink, UMC Utrecht, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:18

PsA patients: highest risk of developing NAFLD

Presented By

Mr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:09

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

Genital psoriasis: high prevalence, often underdiagnosed

Presented By

Dr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:12

Novel oral psoriasis drug maintains efficacy over 2 years

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK-PSO-1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:36

Systemic treatment for psoriasis: what is on the horizon?

Presented By

Prof. Diamant Thaci , University of Lübeck, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:45

Topical therapy in psoriasis: an important partner in combination therapy

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Centre, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:40

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Presented By

Dr Marieke Seyger , Radboud University Medical Centre, the Netherlands

Trial

Phase 3, IXORA-PEDS

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:30

Psoriasis patients see great benefit in achieving complete skin clearance

Presented By

Prof. Matthias Augustin , University Medical Centre Hamburg, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:25

Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib

Presented By

Prof. Mark Lebwohl , Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK PSO-1, POETYK PSO-2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:50

Dose tapering in psoriasis is associated with a low relapse rate

Presented By

Dr Juan Raul Castro Ayarza , Medicarte, Colombia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:43

Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Presented By

Prof. Lars Erik Kristensen , Copenhagen University Hospital, Denmark

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:30

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:24

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By

Prof. Kenneth Gordon, Medical College of Wisconsin, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:09

Novel developments in topical psoriasis therapy

Presented By

Prof. April Armstrong, University of Southern California Keck School of Medicine, USA

Trial

Phase 3, PSOARING; PSO-LONG

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:06

JAK inhibitors: A risk assessment

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:59

Intestinal microbe-preparation: Modest activity but safe for mild psoriasis

Presented By

Dr Douglas Maslin

Trial

Phase 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:40

Potential biomarker discovered for treatment response to ustekinumab

Presented By

Mr Shane Solanky, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:46

TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis

Presented By

Dr Nikolai Loft, Copenhagen University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:08

Secukinumab also tolerable in paediatric psoriasis patients

Presented By

Prof. Michael Sticherling, University Erlangen–Nürnberg, Germany

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:22

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By

Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Trial

Phase 3, UNCOVER

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:15

The Yin and Yang of opposing vectors: an explanation for side effects of biologics

Presented By

Prof. Curdin Conrad, Lausanne University Hospital, Switzerland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:07

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

DLQI scores underestimated during lockdowns?

Presented By

Dr Ali Alsharqi, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:34

TNF blockers likely beneficial for psoriatic patients with COVID-19

Presented By

Prof. Catherine Smith, King’s College London, UK

Trial

PsoProtect

Conference

PFG 2021

Type

Peer-reviewed article

2 February 2022 15:42

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:22

IL-36 gene expression in GPP lesions reduced by spesolimab

Presented By

Dr Ahmed Farag

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:09

Inhibition of heat shock protein: A novel way to treat psoriasis?

Presented By

Dr Anne Bregnhøj, Aarhus University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:02

Risankizumab superior to ustekinumab in skin histopathology scores

Presented By

Dr Kathleen Smith

Trial

Phase 3, UltiMMa-1 trial

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:49

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By

Dr Juul van den Reek , Radboudumc, the Netherlands

Trial

Phase 4, CONDOR

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:43

Intermediate monocytes are possible predictors of response to secukinumab

Presented By

Dr Jonathan Hardman-Smart, King’s College London, UK

Trial

Phase 3, SIGNATURE

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:34

Gut microbiota of psoriasis patients: less diverse and reduced functionality

Presented By

Dr Tanja Todberg, University of Copenhagen, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:29

Psoriasis associated with a higher cancer risk

Presented By

Mr Alex Trafford, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:23

Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status

Presented By

Dr Ravi Ramessur, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:20

Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation

Presented By

Dr Niamh Kearney, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:16

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By

Dr Teresa Tsakok, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:37

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

Age at disease onset: a key factor in understanding psoriasis

Type

News article

2 December 2021 17:26

Comparing routes of administration of methotrexate in psoriasis patients

Presented By

Mr Ishan Agrawal, Siksha O Anusandhan University Bhubaneswar, India

Conference

ICD 2021

Type

News article

2 December 2021 17:24

Paediatric dermatology in Tunisia: common diagnoses

Presented By

Dr Nejib Doss, Military Hospital of Tunis, Tunisia

Conference

ICD 2021

Type

News article

2 December 2021 17:08

ICD 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ICD 2021

29 November 2021 09:20

TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, POETYK PSO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:31

Tapinarof cream for psoriasis leads to high clearance rates and remittive effect

Presented By

Dr Linda Stein Gold, Henry Ford Health System, USA

Trial

PSOARING 3

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:30

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

Treating psoriasis during pregnancies

Presented By

Prof. Mahira Hamdy El Sayed, Ain Shams University, Egypt

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:18

A patient-related approach to freedom of disease

Presented By

Elfie Deprez , Ghent University Hospital, Belgium

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:17

Ixekizumab superior to secukinumab in real-world psoriasis study

Presented By

Dr Caterina Cariti, University of Turin, Italy

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:16

Nail psoriasis: An important target to be treated

Presented By

Prof. Peter van de Kerkhof , Radboudumc, the Netherlands

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:15

Grand debate: Is psoriasis a systemic or skin-only disease?

Presented By

Prof. Brian Kirby & Prof. Stefano Piaserico

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:14

EADV 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

PSOARING 3, JADE-DARE, HEADS UP

Conference

EADV 2021

19 October 2021 00:08

Real-world data on brodalumab affirms efficacy and fast onset of action

Presented By

Dr Ralph Von Kiedrowski

Trial

LIBERO

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:35

Bimekizumab in psoriasis: Up-and-coming

Presented By

Prof. Bruce Strober, Yale University, USA

Trial

Phase 3, BE VIVID

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:34

Biologic psoriasis treatment and COVID-19 risk: Contradictory results

Presented By

Dr Anne-Claire Fougerousse; Dr Giovanni Damiani

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:12

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3, OASIS-2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:44

Promising results with nanobody treatment in psoriasis

Presented By

Dr Kim A. Papp, Probity Medical Research, Canada

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:40

Efficacious non-steroidal topical for psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, PSOARING

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:28

How to manage cutaneous side effects of immunotherapy

Presented By

Prof. Jennifer N. Choi, Northwestern Feinberg School of Medicine, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 09:02

Cannabinoids: a future role in dermatology?

Presented By

Prof. Adam Friedman, School of Medicine & Health Sciences, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 09:01

Psoriasis therapy for children and pregnancies

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

CRIB, CADMUS, IXORA-PEDS

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:03

Biologic psoriasis treatment to lower cardiovascular risk?

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:01

A new topical PDE-4 inhibitor effective in psoriasis

Presented By

Prof. Mark Lebwohl

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:00

IL-17A and IL-17F blockade remarkably effective in psoriasis

Presented By

Prof. Kristian Reich; Prof. Kenneth B. Gordon

Trial

BE VIVID and BE READY

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:09

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Presented By

Prof. Richard B. Warren

Trial

IMMerge

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:07

Tape stripping – a painless way to distinguish AD and psoriasis?

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:05

Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?

Presented By

Dr Nikolai Klebanov , Brigham and Women’s Hospital, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:01

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:42

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:12

Psoriasis onset determines sequence of symptoms

Presented By

Prof. Umut Kalyoncu, Hacettepe University, Turkey

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:07

Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Trial

Phase 3, DISCOVER

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 19:53

IL-17A blocker effective in paediatric psoriasis patients

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3, IXORA-PEDS

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 20:51

Small molecules: interesting novel treatment options in AD

Presented By

Prof. Tilo Biedermann, Helmholtz Center Munich, German

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 20:27

Biologics: increasingly used in paediatric dermatology

Presented By

Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 15:16

Comorbidities more common in chronic urticaria, psoriasis, and AD

Presented By

Dr Karsten Weller, Charité University Hospital, Germany

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 20:40

IL-17 blocker: effective and safe in patients with comorbidities

Presented By

Dr Alice Gottlieb, Tufts University School of Medicine, USA

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 20:19

Reduced sleep quality in dermatoses influenced by itch and pain

Presented By

Dr Karolina Kaaz, Wroclaw Medical University, Poland

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 19:58

ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ESPRIT

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 19:23

Relationship psoriasis and NAFLD: new data on the hepato-dermal axis

Presented By

Dr Daniel Nieto, La Paz Hospital, Spain

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 18:25

Novel selective IL-23 blocker equally effective in patients with metabolic syndrome

Presented By

Dr Alice Gottlieb, Tufts University School of Medicine, USA

Trial

reSURFACE 1 and 2

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 17:28

Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 16:30

Certolizumab pegol efficacious for head and neck psoriasis

Presented By

Prof. Peter van de Kerkhof, Radboud University, the Netherlands

Trial

Phase 3, CIMPASI-1 and CIMPASI-2

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 15:02

No hint of teratogenicity through ixekizumab

Presented By

Prof. Alexander Egeberg, Herlev and Gentofte Hospital, Denmark

Trial

PSOLAR

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 14:32

Novel treatment options for many dermatologic indications

Presented By

Prof. Lone Sko; Prof. Lars Iversen

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 20:13

Biologics: biosimilars and lifestyle

Conference

WCD 2019

26 August 2019 20:06

Choosing the right biologic in psoriasis

Presented By

Prof. Nick Reynolds, Newcastle University, United Kingdom

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 19:08

Novel selective IL-23 blocker highly effective over 2 years

Trial

Phase 3, IMMhance

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 11:52

Registries – an important research tool in biologics

Presented By

Prof. Bruce E. Strober, UConn Health, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 10:10

Favourable safety profile of long-term use of ixekizumab

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 22:50

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Presented By

Dr Sandra Philipp, Charité-Universitätsmedizin Berlin, Germany

Trial

Phase 3, AMAGINE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 21:59

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Presented By

Dr Gayle van der Kraaij, Amsterdam UMC, the Netherlands

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 20:57

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By

Prof. Jonathan Barker, Kings College London, United Kingdom

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 20:34

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients

Presented By

Dr Sandra Phillip, Charité-Universitätsmedizin Berlin, Germany

Trial

Phase 3, CADMUS Jr

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 19:59

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

ECLIPSE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:23

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:02

ABP501 biosimilar for adalimumab: What you need to know

Presented By

Prof. Brian Kirby, St Vincent's Hospital, Dublin, Ireland

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 17:24

Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 16:26

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Presented By

Prof. Lluís Puig, Hospital de la Santa Creu i Sant Pau, Spain

Trial

Phase 3, AMAGINE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 15:29

Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 3, CIMPASI

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 15:05

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis

Presented By

Dr Nehal Mehta; Prof. Emma Guttman-Yassky

Trial

NHANES

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 14:38

Atopic dermatitis and psoriasis: on a spectrum?

Presented By

Prof. Emma Guttman-Yassky, Mount Sinai Medical School, USA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 13:39

Treatment goals in psoriasis

Presented By

Prof. Ulrich Mrowietz

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 12:44

Small molecules, apremilast, and TYK2

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ESTEEM, PALACE, LIBERATE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 09:45

IBD risk of treatment with IL-17 antagonists

Presented By

Dr Wolfgang Eigner, Medical University of Vienna, Austria

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:37

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ERASURE/FIXTURE

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 23:10

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:06

Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

BE ABLE

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 19:24

Serlopitant reduces pruritus associated with psoriasis

Presented By

Dr David Pariser, Pariser Dermatology Specialists Virginia, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:38

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06

Better gastrointestinal tolerability with biologics than the conventional therapy

Conference

AAD 2018

Type

Peer-reviewed article

21 December 2018 17:56

Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab

Presented By

Dr Jennifer Cather

Trial

Aesthetics Center in Dallas, USA

Conference

AAD 2018

Type

Peer-reviewed article

21 December 2018 15:59

Intralesional cryosurgery and itching in psoriasis

Presented By

Prof. Yaron Har-Shai, University of Technion, Israel; Dr Philippa Dickison, University of Sydney, Australia

Conference

AAD 2018

Type

Peer-reviewed article

21 December 2018 14:03

Oral therapeutics, supersaturation and excimer laser

Presented By

Dr John Koo, University of California San Francisco, USA

Trial

ESTEEM 2

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 18:15

Psoriasis management online?

Presented By

Prof. April Armstrong, Keck School of Medicine, University of Southern California, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 12:25